These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33169241)

  • 21. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Abbas N; Bruland ØS; Brevik EM; Dahle J
    Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
    Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted beta therapy of prostate cancer with
    Yeh MC; Tse BWC; Fletcher NL; Houston ZH; Lund M; Volpert M; Stewart C; Sokolowski KA; Jeet V; Thurecht KJ; Campbell DH; Walsh BJ; Nelson CC; Russell PJ
    EJNMMI Res; 2020 May; 10(1):46. PubMed ID: 32382920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
    Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
    Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
    Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
    Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
    Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
    Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
    Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.
    Lindenblatt D; Fischer E; Cohrs S; Schibli R; Grünberg J
    EJNMMI Res; 2014 Dec; 4(1):54. PubMed ID: 26116117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.
    Reilly RM; Georgiou CJ; Brown MK; Cai Z
    EJNMMI Radiopharm Chem; 2024 May; 9(1):37. PubMed ID: 38703297
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.